Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)Depreciation ExpenseEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetShares Issued
Ratios

Vivos Therapeutics (VVOS) Non-Current Receivables (2019 - 2021)

Vivos Therapeutics' Non-Current Receivables history spans 3 years, with the latest figure at $842290.0 for Q3 2021.

  • Quarterly results put Non-Current Receivables at $842290.0 for Q3 2021, changed N/A from a year ago — trailing twelve months through Sep 2021 was $842290.0 (changed N/A YoY), and the annual figure for FY2020 was $811000.0, up 3.3%.
  • Non-Current Receivables for Q3 2021 was $842290.0 at Vivos Therapeutics, roughly flat from $846214.0 in the prior quarter.
  • In the past five years, Non-Current Receivables ranged from a high of $846214.0 in Q2 2021 to a low of $785061.0 in Q4 2019.
  • The 3-year median for Non-Current Receivables is $816584.0 (2021), against an average of $820229.8.
  • Peak annual rise in Non-Current Receivables hit 3.3% in 2020, while the deepest fall reached 3.3% in 2020.
  • Year by year, Non-Current Receivables stood at $785061.0 in 2019, then rose by 3.3% to $811000.0 in 2020, then increased by 3.86% to $842290.0 in 2021.
  • According to Business Quant data, Non-Current Receivables over the past three periods came in at $842290.0, $846214.0, and $816584.0 for Q3 2021, Q2 2021, and Q1 2021 respectively.